Chargement en cours...
nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
INTRODUCTION: The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2. METHODS: Chemother...
Enregistré dans:
| Publié dans: | Front Oncol |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6066533/ https://ncbi.nlm.nih.gov/pubmed/30087850 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2018.00253 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|